THIRTEEN WEEK ORAL TOXICITY STUDY OF P-XSC IN DOGS

癌症预防和预防司化学预防处 国家卡纳研究所的控制部门指示一个项目来识别和 开发人类使用的药物，以防止、延缓或逆转 细胞异型增生(如上皮内瘤变)进展为 浸润性癌症。药物研发过程的一部分 涉及临床前毒理学研究。这些研究是进行的 根据发布的指导文件，遵循良好的实验室操作规范 由食品和药物管理局提供，用于支持 研究中的新药申请和最终的新药申请 到癌症化学预防药物的上市批准。 承包商应进行为期13周的1，4- 对狗的亚甲基亚硫氰酸亚苯酯。在之前的一项关于 观察到这种复合性的血小板减少症。这项研究旨在 评估这种效应的机制，并检验这一假设 是基于药物诱导的免疫反应。

The Chemoprevention Branch of the Division of Cancer Prevention and Control at the National Caner Institute directs a program to identify and develop drugs for human use that will prevent, delay, or reverse the progression of cellular dysplasia (e.g. intraepithelial neoplasia) to invasive cancer. part of the drug research and development process involves preclinical toxicology studies. These studies are performed under Good Laboratory Practices according to guidance documents published by the Food and Drug Administration and are used to support Investigational New Drug applications and eventually New Drug Applications to the marketing approval of cancer chemopreventive agents. The contractor shall conduct a 13-week toxicity study of 1,4- Phenylenebis(methylene) selenocyanate in dogs. In a previous study of this compound thrombocytopenia was observed. This study is designed to evaluate the mechanism of this effect and to test the hypothesis that it is based on a drug-induced immune response.